PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph plus ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.

被引：0

作者：

Cortes, Jorge E.

Kim, Dong-Wook

Pinilla-Ibarz, Javier

Paquette, Ronald

le Coutre, Philipp D.

Chuah, Charles

Nicolini, Franck E.

Apperley, Jane

Khoury, Hanna Jean

Talpaz, Moshe

DiPersio, John F.

DeAngelo, Daniel J.

Rea, Delphine

Abruzzese, Elisabetta

Mueller, Martin C.

Baccarani, Michele

Gambacorti-Passerini, Carlo

Turner, Christopher D.

Haluska, Frank G.

Kantarjian, Hagop

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Catholic Univ Korea, Seoul, South Korea

[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[4] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA

[5] Charite, D-13353 Berlin, Germany

[6] Singapore Gen Hosp, Singapore, Singapore

[7] Ctr Hosp Lyon Sud, Pierre Benite, France

[8] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England

[9] Emory Winship Canc Inst, Atlanta, GA USA

[10] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[11] Washington Univ, Sch Med, St Louis, MO USA

[12] Dana Farber Canc Inst, Boston, MA 02115 USA

[13] Hop St Louis, Serv Malad Sang, Paris, France

[14] Osped S Eugenio, Rome, Italy

[15] Heidelberg Univ, Med Fak Mannheim, Med Klin 3, Mannheim, Germany

[16] Univ Hosp Bologna, Bologna, Italy

[17] Univ Milano Bicocca, Azienda Osped San Gerardo, Unita Ric Clin Ematol, Monza, Italy

[18] ARIAD Pharmaceut, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6503

引用

页数：2

共 50 条

[21] Safety and efficacy study of subcutaneous homoharringtonine (SC HHT) in imatinib (IM)-resistant chronic myeloid leukemia (CML) with the T315I mutation - Initial report of a phase II trial [J].

Khoury, H. Jean ;

Michallet, Mauricette ;

Corm, Selim ;

Roy, Lydia ;

Jones, Dan ;

Hochhaus, Andres ;

Kantarjian, Hagop ;

Benichou, Annie-Claude ;

Scwartz, Richard ;

Cortes, Jorge .

BLOOD, 2007, 110 (11) :318A-318A

[22] Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study [J].

Kensuke Usuki ;

Arinobu Tojo ;

Yasuhiro Maeda ;

Yukio Kobayashi ;

Akira Matsuda ;

Kazuma Ohyashiki ;

Chiaki Nakaseko ;

Tatsuya Kawaguchi ;

Hideo Tanaka ;

Koichi Miyamura ;

Yasushi Miyazaki ;

Shinichiro Okamoto ;

Kenji Oritani ;

Masaya Okada ;

Noriko Usui ;

Tadashi Nagai ;

Taro Amagasaki ;

Aira Wanajo ;

Tomoki Naoe .

International Journal of Hematology, 2012, 95 :409-419

[23] A PHASE I/II STUDY OF NILOTINIB IN JAPANESE PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) OR RELAPSED/REFRACTORY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) [J].

Usuki, K. ;

Urabe, A. ;

Tojo, A. ;

Maeda, Y. ;

Kobayashi, Y. ;

Jinnai, I. ;

Ohyashiki, K. ;

Nishimura, M. ;

Kawaguchi, T. ;

Tanaka, H. ;

Miyamura, K. ;

Miyazaki, Y. ;

Hughes, T. ;

Branford, S. ;

Okamoto, S. ;

Ishikawa, J. ;

Okada, M. ;

Usui, N. ;

Amagasaki, T. ;

Natori, H. ;

Naoe, T. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 :433-434

[24] A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph plus acute lymphoblastic leukemia (ALL) [J].

Larson, R. ;

Ottman, O. ;

Kantarjian, H. ;

le Coutre, P. ;

Baccarani, M. ;

Weitzman, A. ;

Giles, F. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

[25] Impact of Allogeneic Stem Cell Transplantation as Salvage Therapy After T315I Mutation Detection in Chronic Myeloid Leukemia (CML) and Ph plus Acute Lymphoblastic Leukemia (ALL) Patients [J].

Nicolini, Franck Emmanuel ;

Zhou, Wei ;

Martinelli, Giovanni ;

Mauro, Michael J. ;

Hochhaus, Andreas ;

Su, Jing ;

Apperley, Jane ;

Chuah, Charles ;

Dufva, Inge ;

Kim, Dong-Wook ;

Giles, Francis J. ;

Peter, Senaka ;

Cortes, Jorge .

BLOOD, 2009, 114 (22) :268-268

[26] Hematologic safety data of single-agent ponatinib from a phase I and phase II trial in Philadelphia chromosome-positive (Ph plus ) CML/ALL patients. [J].

Greer, Devon M. ;

Liewer, Susanna ;

Akhtari, Mojtaba .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[27] Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph plus CML-CP) with and without the T315I Mutation [J].

Combes, Francois Pierre ;

Li, Ying Fei ;

Sy, Sherwin K. B. ;

Lorenzo, Sebastien ;

Dasgupta, Kohinoor ;

Kapoor, Shruti ;

Hoch, Matthias ;

Ho, Yu-Yun .

BLOOD, 2022, 140 :6791-6792

[28] Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation [J].

Cortes, Jorge ;

Lipton, Jeff H. ;

Rea, Delphine ;

Digumarti, Raghunadharao ;

Chuah, Charles ;

Nanda, Nisha ;

Benichou, Annie-Claude ;

Craig, Adam R. ;

Michallet, Mauricette ;

Nicolini, Franck E. ;

Kantarjian, Hagop .

BLOOD, 2012, 120 (13) :2573-2580

[29] AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without the T315I Mutation [J].

Levy, Moshe Y. ;

Mauro, Michael J. ;

Issa, Ghayas C. ;

Andorsky, David ;

Tomassetti, Sarah ;

Broun, E. Randolph ;

Maegawa, Rodrigo ;

Deininger, Michael .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 :S298-S298

[30] FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation [J].

Pamuk, Gulsum E. ;

Chow, Edwin C. Y. ;

Ionan, Alexei C. ;

Chen, Haiyan ;

Lee, Shwu-Luan ;

Hsu, Vicky ;

Grimstein, Manuela ;

Zheng, Nan ;

Sun, Jielin ;

Charlab, Rosane ;

Gehrke, Brenda J. ;

Vallejo, Jonathon ;

Ehrlich, Lori A. ;

de Claro, R. Angelo ;

Theoret, Marc R. .

CLINICAL CANCER RESEARCH, 2024, 30 (19) :4266-4271

← 1 2 3 4 5 →